Clinical Trial Update: A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing MAb-3F8 plus GM-CSF to 13-cis-retinoic acid plus GM-CSF in patients with primary refractory neuroblastoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)
• MAb-3F8
• sargramostim (sargramostim)

Snippet

Sponsor: United Therapeutics | Conditions: Primary Refractory Neuroblastoma | Phase 2 | Status: TERMINATED